Zymeworks Inc. announced on February 26, 2025, the achievement of a $14 million cash research milestone from GSK. This payment is associated with a clinical milestone under their 2016 platform technology transfer and license agreement.
Under the terms of this agreement, Zymeworks granted GSK a worldwide, royalty-bearing exclusive license to research, develop, and commercialize up to six bispecific antibodies generated using Zymeworks' proprietary Azymetric™ platform. The agreement was expanded in May 2019 to include access to Zymeworks’ heavy-light chain pairing technology.
This milestone payment contributes to Zymeworks' financial resources and validates its Azymetric platform. The company remains eligible to receive research, development, and commercial milestone payments of up to $1.1 billion from GSK, in addition to tiered royalties on worldwide sales, highlighting the long-term value of its strategic partnerships.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.